MNPR - NASDAQ
Monopar Therapeutics Inc.
$60.56
-1.1%Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.
At a Glance
Live SnapshotMonopar Therapeutics Inc. Management Team
Dr. Patrice P. Rioux M.D., Ph.D.
Acting Chief Medical Officer
Mr. Quan Anh Vu
Chief Financial Officer, Principal accounting officer & Principal financial officer
Mr. Andrew J. Cittadine M.B.A.
Chief Operating Officer
Compensation
$542,544
Dr. Christopher M. Starr Ph.D.
Co-Founder & Independent Executive Chairman of the Board
Compensation
$200,000
Dr. Chandler D. Robinson M.B.A., M.D., M.Sc., MBA, MSc
Co-Founder, Chief Executive Officer, President & Director
Compensation
$1,144,480
Monopar Therapeutics Inc. Insider Positioning
During the last 12 months, insiders have purchased $105K and sold $37.01M worth of MNPR shares, resulting in $36.91M of net selling activity.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
1.5K
104.92K
4.7K
312.50K
-208K
-$208K
6-9 Months
0
0.00
550.2K
35.00M
-35.0M
-$35.00M
9-12 Months
0
0.00
42.5K
1.70M
-1.7M
-$1.70M
Top Buyers
Vu Quan Anh
Officer: Chief Financial Officer
$105K
Top Sellers
Tactic Pharma Llc
10 Percent Owner
$35.00M
Robinson Chandler
Director, Officer: Chief Executive Officer
$672K
Starr Christopher M
Director
$672K
Tsuchimoto Kim R
Director
$356K
Klausner Arthur J
Director
$312K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $36.91M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Insider Participation
5 insider sellers vs. 1 buyers. Widespread selling across multiple insiders may signal concerns.
SEC Filings
MNPR - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 30, 2026 | June 22, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 30, 2025 | June 17, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | July 22, 2024 | August 05, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 28, 2023 | June 27, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 29, 2022 | June 28, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 30, 2021 | June 30, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 29, 2020 | June 11, 2020 | 2020 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.